Question Everything. See who's reporting it.

ZoeNCure Licenses Novel Antibody Tech for Dual-Payload ADCs in Liver Cancer

Source: The Hindu

The story in brief

ZoeNCure Therapeutics Pvt. Ltd., based in New Delhi, India, has secured a license for a novel antibody platform from San Diego-based Styx Biotechnologies to develop next-generation ADCs for liver cancer. The collaboration targets hepatocellular carcinoma, a critical unmet medical need in South Asia, with therapies designed to deliver dual therapeutic mechanisms.

NEWXFree on Android and iPhone. Open in NEWX